$10.97
-0.05 (-0.45%)
Open$11.19
Previous Close$11.02
Day High$11.35
Day Low$10.83
52W High$25.37
52W Low$13.49
Volume—
Avg Volume532.0K
Market Cap51.49M
P/E Ratio15.06
EPS$1.27
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+82.0% upside
Current
$10.97
$10.97
Target
$19.97
$19.97
$17.96
$19.97 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.10M | 46.49M | 39.49M |
| Net Income | 3.70M | 3.34M | 2.56M |
| Profit Margin | 8.2% | 7.2% | 6.5% |
| EBITDA | 5.80M | 5.78M | 5.15M |
| Free Cash Flow | 3.02M | 2.12M | 2.20M |
| Rev Growth | +4.3% | +20.2% | +6.0% |
| Debt/Equity | 0.88 | 1.05 | 1.14 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |